
News | Press releases & other news
Press releases
Nov 17, 2026
Correction: Lytix Biopharma ASA: Key information relating to the subsequent offeringRead more...Nov 17, 2026
Lytix Biopharma ASA: Ex. subsequent offeringRead more...Nov 17, 2026
Lytix Biopharma ASA: Key information relating to the subsequent offeringRead more...Nov 17, 2026
Lytix Biopharma ASA - Mandatory notification of trade by close associates to primary insidersRead more...Nov 17, 2026
Lytix Biopharma ASA: Private placement and retail offer via Nordnet successfully completedRead more...Nov 17, 2026
Lytix Biopharma ASA: Contemplated private placement and retail offer via NordnetRead more...Nov 12, 2026
Lytix Biopharma Q3 2026: Positive NeoLIPA Results Strengthen Basis for Phase III in MelanomaRead more...Nov 8, 2026
Lytix Biopharma to Present NeoLIPA Phase II Results in Late-Breaking Oral Presentation at ESMO IO 2026Read more...Nov 8, 2026
Lytix Biopharma presenterer late-breaking fase II-resultater fra NeoLIPA på ESMO IO 2026Read more...Nov 6, 2026
Lytix Biopharma: Invitation to the Q3 2026 Results PresentationRead more...Nov 4, 2026
Research Council of Norway awards Lytix Biopharma NOK 12 million to extend its oncolytic platform to deep-seated tumorsRead more...Nov 2, 2026
Lytix Biopharma announces ruxotemitide plus pembrolizumab meets primary endpoint in Phase II NeoLIPA study in resectable melanomaRead more...Nov 2, 2026
Lytix Biopharma kunngjør at ruxotemitide i kombinasjon med pembrolizumab har nådd det primære endepunktet i fase II-studien NeoLIPA i pasienter med operabelt melanomRead more...Oct 19, 2026
Finansiell kalenderRead more...Oct 19, 2026
Financial calendarRead more...Sep 3, 2026
Lytix Biopharma ASA: Grant of share options to management and key personnelRead more...Sep 2, 2026
Lytix Biopharma ASA: Mandatory notification of trade by primary insiderRead more...Aug 26, 2026
Lytix Biopharma Q2 2026: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma, Marking Defining MilestoneRead more...Aug 26, 2026
FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk MelanomaRead more...Aug 26, 2026
Lytix to Partner with Leading Investigator on ALETTA Study Testing Ruxotemitide in Combination with Ipilimumab and Nivolumab in Early-stage Resectable MelanomaRead more...
For the full archive of regulatory news releases, visit Oslo Børs NewsWeb.
Visit Oslo Børs NewsWeb